ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics
Menée sur des échantillons tumoraux prélevés sur des patientes atteintes d'un cancer du sein métastatique, puis in vitro et in vivo, cette étude française évalue l'association entre l'expression de ATIP3 et la survie des patientes, puis met en évidence le rôle joué par cette protéine dans la répression du processus métastatique
Metastasis, a fatal complication of breast cancer, does not fully benefit from available therapies. In this study we investigated whether ATIP3, the major product of 8p22 MTUS1 gene, may be a novel biomarker and therapeutic target for metastatic breast tumors. We show that ATIP3 is a prognostic marker for overall survival among patients with breast cancer. Notably, among metastatic tumors, low ATIP3 levels associate with decreased survival of the patients. By using a well-defined experimental mouse model of cancer metastasis we show that ATIP3 expression delays the time-course of metastatic progression and limits the number and size of metastases in vivo. In functional studies, ATIP3 silencing increases breast cancer cell migration whereas ATIP3 expression significantly reduces cell motility and directionality. We report here that ATIP3 is a potent microtubule stabilizing protein whose depletion increases microtubule dynamics. Our data support the notion that by decreasing microtubule dynamics, ATIP3 controls the ability of microtubule tips to reach the cell cortex during migration, a mechanism that may account for reduced cancer cell motility and metastasis. Of interest, we identify a functional ATIP3 domain that associates with microtubules and recapitulates the effects of ATIP3 on microtubule dynamics, cell proliferation and migration. Our study is a major step toward the development of new personalized treatments against metastatic breast tumors that have lost ATIP3 expression.
Cancer Research , résumé, 2013